Developing scalable cell replacement therapies for the world

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treat incurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety.

We are also establishing processes for manufacturing and controls and instituting GMP manufacturing and GLP studies to cater to market needs worldwide. Our lead product out of the platform is EyecyteRPE aimed at treating Dry AMD (Age-related Macular Degeneration). Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide. We are currently targeting phase-one trials for EyecyteRPE in the later half of 2020.

Recent Scientific Papers

A lovely picture of #RPE cells grown in our lab for treatment of #dryAMD

Hats off to the resilience of such parents but the real issue is the 16 Cr/vial !! Novartis announced closure of one of its Zolgensma plants due to insufficient demand so something's gotta give. We need to democratize access to these life saving cures.https://www.fiercepharma.com/manufacturing/after-overestimating-demand-novartis-shutting-down-colorado-plant?utm_source=dlvr.it&utm_medium=linkedin https://twitter.com/ChaddaSrishti/status/1375453774278316035

Career Openings

Research Associate

Project: Hands-on experience in gene editing tools like ZFN, TALEN, CRISPR/Cas9 preferred

Junior / Senior Research Fellow

Project: Hands-on experience in mammalian cell and tissue culture (preferably with stem or progenitor cells) and basic cell biology techniques

View all